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Response to correspondence concerning: “Early
hydroxychloroquine but not chloroquine use
reduces ICU admission in COVID-19 patients”
We would like to thank all our colleagues for taking the
opportunity to start a scientific discussion on the matter of
hydroxychloroquine in COVID-19. We feel that it is important in
the current climate, where politics and economics interfere with
the scientific domain, to have a calm and scientific discussion on
this topic. Below you will find our response to the letters.
Authors’ reply:
The first letter “Comparison of hospital treatment strategy or
of treatment actually received in COVID-19?” asks us about our
methodology. We understand the nature of the question quite well,
since we have discussed this issue before deciding which analysis
strategy to choose. Clearly, this is an observational study that might
be prone to potential bias. To avoid this, we used a two-step
procedure. The first step encompasses the inclusion of patients.
The second step involves the comparison of treated and untreated
patients after their hospitalization.
The inclusion of patients for our study was based on hospital
treatment strategy. Patients were admitted to a HCQ, CQ or non-
treatment hospital randomly; the hospital policy regarding the use
of HCQ/CQ was not communicated to the patient beforehand,
neither was it part of a selection procedure for the study. Thus, the
fact that a patient was admitted to a HCQ, CQ or non-treatment
hospital was a random event and based on a random assignment,
based on geographical loction only. That is the reason why we
believe that our study design and patient inclusion approaches the
intention-to-treat strategy used in randomized-controlled trials.
The assignment to receive HCQ or CQ treatment occurs after
hospitalization and is influenced by patient characteristics, such as
co-morbidity. This means that the actual assignment of a
treatment may lead to differences between treated patients and
untreated patients. Thus, to make accurate inferences, it is crucial
to control for confounding by indication and for the differences
between treated and untreated patients. Since the assignment of
treatment occurs after hospitalization, it is independent of the
actual hospital treatment strategy. Therefore, we believe that it is
justified in this second step to pool the data and compare all
treated and untreated patients directly. Subsequently, we used the
propensity score (PS) matching as a balancing score between
treated and untreated patients, and to control for confounding by
indication. PS matching is a proven tool to adjust a treatment effect
for measured confounders in non-randomized studies, such as
ours. At each value of the PS, the distribution of the considered
covariates is the same in the treated and the untreated or control
matching. In our study, after PS matching no significant statistical
differences were found between the baseline characteristics of
treated and untreated patients, including the differences between
hospital strategies (as is shown in Table 1). Furthermore, the type
of hospital treatment was not a confounder in the definite
weighted regression model.
In conclusion, we believe that with our two-step procedure
(hospital treatment strategy at inclusion and actual treatment
received in the analysis), our study limits the influence of potential
bias and enables us to make correct inferences based on the
available data.
The second letter, by Asselbergs et al raises several questions on
the methodology as well.
The authors stated: “in the presence of ICU restriction for
medical reasons or patient preference, analyses on the outcome
‘transfer to ICU’ are limited to patients without ICU restriction, a
particularly selected group. This might impact the generalizability
of the results considerably”.
Since patients with an ICU restriction cannot reach the endpoint
“Transfer to ICU”, we started by computing the outcome as
Composite Adverse Endpoint; taking the two endpoints (Mortality
and Transfer to ICU) together. This eliminates the bias of competing
risk between the two endpoints. We did not consider “Discharge”
as a competing risk, since it was defined as discharge for cure only,
discharge with the expectation of the patient to die for example in
a hospice facility was considered “Death”. To adjust for potential
bias by ICU restriction, we performed stratified analysis for this
“composite adverse endpoint” to reflect underlying potential
differences between the two groups with regard to adverse
incidences and risk factor prevalence. In addition, multivariable
competing risk analysis was conducted; including for ICU
restriction. The hazard ratio (HR) changed from 0.49 without, to
0.47 with ICU restriction. This corresponds with a 4% change, which
is less than the 10% threshold, which is commonly used, if it were a
confounder. With the results of PS matching, competing multivar-
iable risk analyses and stratified analyses, we do not believe that
ICU restriction influenced the effect of HCQ/CQ that we have
reported on ICU admission. Subsequently, we decided to report the
two outcomes separately, after performing additional competing
risk analysis corrections. Here, we did not include patients with an
ICU restriction, therefore our data indeed only describe a possible
protective effect of HCQ in patients without an ICU restriction. As
we described in our discussion, prospective intervention studies
are needed to confirm our results. However, even in randomized
controlled trials generalizability can still be a problem to
extrapolate from the results, although a causal effect has been
shown.
Furthermore, the authors mention that the ICU-population
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reatment groups).
It is suggested that regional differences in infection rates might
ave caused different patient populations. This is unlikely, since 14
utch hospitals participated (from Goes to Groningen, both rural
ospitals as centers in large cities). Fortunately, we did not reach
code black” in the Netherlands, making large differences in ICU
dmission rates unlikely. Obviously, all observational research is at
isk for bias, including selection bias by leaving patients out of the
nalysis that were transferred between hospitals.
For an answer on the question on the methodology of inclusion
y treatment center or treatment exposure, please see our
esponse to the letter by Peters et al. Patients that were directly
dmitted to the ICU or patients that died within the first 24 h after
dmission, were excluded from the analysis. In addition, we have
sed skimming as a routine procedure in our analyses. Separate
ensitivity analyses were performed to investigate whether
mmortal bias or informative censoring could influence our
esults. First, there were no events before the start of the therapy.
econd, time-dependent analysis shows no difference in our
eported results (HRHCQ = 0.47; 95% = 0.27–0.81). Third, in a
ogistic regression analysis we found the same effect of HCQ on ICU
dmission (ORHCQ = 0.40; 0.21–0.77). Thus, neither potential
mmortal bias nor informative censoring had a significant
nfluence on the reported results.
Finally, we would like to thank the authors of the letter by
urger et al, ‘More gastro-intestinal adverse events in non-ICU
ospitalized COVID-19 patients treated with chloroquine versus
ydroxychloroquine’ for sharing the results of their interesting
tudy. The authors show that HCQ has a better safety profile than
Q, with less gastro-intestinal adverse events, and suggest that this
ay partially explain the difference in the risk of transfer to the ICU
hat we found.
We deliberately choose to refrain from collecting data on
dverse effects, since symptoms of COVID-19 are possibly difficult
o distinguish from treatment side-effects, especially in the elderly
opulation, so these results add valuable information on the use of
oth drugs.
In their study,1.3% of the patients discontinued treatment in the
CQ group due to gastro-intestinal adverse events, as compared to
7% in the CQ group (a total of 2 patients on HCQ versus 13 patients
n CQ).
We completely agree with the authors’ suggestion that since the
se of CQ is associated with a higher risk of discontinuation due to
oxicity, more patients in the HCQ are able to complete their
herapy, possibly making it more effective.
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